Tigecycline Dosing
For adults with normal renal and hepatic function, tigecycline is dosed as a 100 mg IV loading dose followed by 50 mg IV every 12 hours. 1
Standard Adult Dosing (Normal Organ Function)
- Loading dose: 100 mg IV over 30-60 minutes
- Maintenance dose: 50 mg IV every 12 hours
- Duration: 5-14 days for complicated skin/intra-abdominal infections; 7-14 days for community-acquired pneumonia 1
The infusion should be administered over 30-60 minutes. This standard regimen applies to patients with normal hepatic and renal function.
Severe Hepatic Impairment (Child-Pugh C)
Reduce the maintenance dose by 50% in patients with severe hepatic impairment. 1
- Loading dose: 100 mg IV (unchanged)
- Maintenance dose: 25 mg IV every 12 hours
- Monitoring: Close monitoring for treatment response is required 1
For Child-Pugh A and B (mild to moderate impairment), no dose adjustment is necessary 1. The rationale for dose reduction in Child-Pugh C patients stems from pharmacokinetic studies showing that tigecycline clearance is reduced by approximately 55% in severe hepatic impairment 2. A study by Korth-Bradley et al. demonstrated that tigecycline clearance decreased from 29.8 L/h in healthy subjects to 13.5 L/h in Child-Pugh C patients 2.
Renal Impairment
No dose adjustment is required for any degree of renal impairment, including patients on hemodialysis. 1, 3
This applies to all levels of renal dysfunction because tigecycline undergoes minimal renal elimination. Pharmacokinetic studies show that renal clearance represents only approximately 20% of total systemic clearance 3. Even in severe renal impairment (creatinine clearance <30 mL/min), tigecycline clearance is reduced by only 20%, with AUC increased by approximately 30%—changes not considered clinically significant 3. Tigecycline is not efficiently removed by hemodialysis and can be administered without regard to dialysis timing 3.
Adolescents (≥40 kg)
For adolescents aged 12-17 years weighing at least 40 kg, use the adult dose of 50 mg IV every 12 hours after a 100 mg loading dose. 1
However, tigecycline use in patients under 18 years is not recommended due to increased mortality observed in adult clinical trials 1. The drug should only be used in pediatric patients when no alternative antibacterial drugs are available 1.
For younger adolescents (8-11 years), if absolutely necessary, the dose is 1.2 mg/kg IV every 12 hours (maximum 50 mg per dose) 1. Use in children under 8 years is contraindicated due to effects on tooth development 1.
Important Clinical Considerations
High-Dose Regimens
While not FDA-approved, higher maintenance doses (100 mg every 12 hours after a 200 mg loading dose) have been used in critically ill patients, particularly for hospital-acquired pneumonia and infections with higher MIC organisms 4, 5. A study showed numerically higher efficacy with 100 mg twice-daily dosing (85%) compared to standard dosing (69.6%) for VAP/HAP 4. However, this approach should be reserved for severe infections when standard dosing is inadequate.
Limitations and Warnings
Tigecycline carries a black box warning for increased all-cause mortality (0.6% absolute risk difference, 95% CI 0.1-1.2%) observed in meta-analyses of clinical trials 1. It should be reserved for situations when alternative treatments are not suitable 1.
The drug is not indicated for diabetic foot infections or hospital-acquired/ventilator-associated pneumonia due to demonstrated inferior outcomes 1.
Monitoring
For patients with severe hepatic impairment receiving reduced doses, monitor treatment response closely. No specific therapeutic drug monitoring is routinely recommended for standard dosing, though critically ill patients may benefit from assessment given the high variability in pharmacokinetics 6.
Tigecycline exhibits extensive tissue distribution (volume of distribution 500-700 L) but achieves relatively low serum concentrations, which may explain suboptimal outcomes in bacteremic infections 1.